Safety, immunogenicity and possible efficacy of immunochemotherapy of persistent Post Kala-azar Dermal Leishmaniasis

Abstract

Post kala-azar dermal leishmaniasis (PKDL) is a common skin condition that follows successful treatment of visceral leishmaniasis (VL) in Sudanese patients. Lesions persist for years in 15% of patients and are viewed as reservoirs for the disease. Drug treatment is protracted, toxic and costly. Cure is strongly correlated with conversion in the leishmanin skin test.